NEW YORK (TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP - Get Report), to discuss the company's new treatment.Kidron said there are three stages in which patients with Type II diabetes act to treat it: changing their diet and lifestyle, taking medicine orally, and finally, using insulin pumps or injections. Oramed has created an ingestible insulin pill that patients would take in the second stage of their process. By administering the drug early enough, Kidron said, the patient's need to use insulin injections or pumps would be postponed. He added that oral administration is much better than injection. By performing the latter, the insulin is injected directly into the bloodstream, whereas an ingestible pill goes first to the liver, which regulates the secretion of insulin into the bloodstream. Kidron concluded that it's an exciting time, as the company is expected to complete a Phase II trial for the drug by the end of the year, and is also working on a similar project for Type I diabetes. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
More from Opinion
Microsoft Is a Pricey Stock That's Worth Every Penny
If there is a momentum stock that deserves to trade at fairly rich valuations while still showing potential for further price appreciation, Microsoft is it.
JPMorgan Proves It Has the Best Franchise in Banking, Despite Trimmed Outlook
Investors might have been spooked at first by the unfavorable impact of lower rates on net interest income. Yet, JPMorgan is likely the best bank stock to own amid an uncertain macroeconomic environment.
Schlumberger Is a Dominant Energy Player Patiently Waiting to Shine
Despite the usual short-term headwinds, Schlumberger seems to be one of the best-positioned players in the energy services sector. Once the macro environment improves, the stock could head substantially higher from its current, depressed levels.